Product Description
LIDOCAINE (LYE doe kane) is an anesthetic. It causes loss of feeling in the skin and surrounding tissues. It is used to prevent and to treat pain from some procedures. This medicine is also used to treat minor burns, scrapes and insect bites. (Sourced from: https://my.clevelandclinic.org/health/drugs/19854-lidocaine-skin-cream-or-ointment)
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Topical,Transdermal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Neuralgia | Pain Unspecified | Anastesia Related
Known Adverse Events: Erythema | Pruritus | Drug Hypersensitivity | Hypersensitivity, Immediate | Hyperemia | Headache
Company: ZARS Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, China, France, Germany, Italy, Japan, Spain, United Kingdom, United States, Unknown Location
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Anesthesia Related|Cesarean Section|Collagen Diseases|Facial Nerve Diseases|Facial Pain|Injuries/wounds Unspecified|Intervertebral Disc Degeneration|Low Back Pain|Neuralgia, Postherpetic|Neuromyelitis Optica|Neuropathic Pain|Other|Pain Unspecified|Premature Ejaculation
Phase 2: Abdominal Pain|Chronic Pain|Hearing Loss, Bilateral|Ileus|Infertility|Keratosis, Actinic|Pelvic Pain
Phase 1: Diabetic Foot|Glaucoma|Healthy Volunteers|Idiopathic Pulmonary Fibrosis|Lung Diseases, Interstitial|Neuralgia|Progressive Pulmonary Fibrosis|Skin Ulcer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SENS-501-101 | P2 |
Not yet recruiting |
Hearing Loss, Bilateral |
2030-12-31 |
|
| ACTRN12624000785505 | P1 |
Not yet recruiting |
Glaucoma |
2025-10-01 |
|
| jRCT2031240211 | P3 |
Recruiting |
Neuralgia, Postherpetic |
2025-06-30 |
|
| M21-784 | P3 |
Active, not recruiting |
Neuromyelitis Optica |
2025-05-28 |
82% |